Novel mutation in CCBE 1 as a cause of recurrent hydrops fetalis from Hennekam lymphangiectasia-lymphedema syndrome-1. by Melber, Dora J et al.
UC San Diego
UC San Diego Previously Published Works
Title
Novel mutation in CCBE 1 as a cause of recurrent hydrops fetalis from Hennekam 
lymphangiectasia-lymphedema syndrome-1.
Permalink
https://escholarship.org/uc/item/67x070hr
Journal
Clinical case reports, 6(12)
ISSN
2050-0904
Authors
Melber, Dora J
Andreasen, Tara S
Mao, Rong
et al.
Publication Date
2018-12-01
DOI
10.1002/ccr3.1804
 
Peer reviewed
eScholarship.org Powered by the California Digital Library
University of California
2358  |    Clin Case Rep. 2018;6:2358–2363.wileyonlinelibrary.com/journal/ccr3
1 |  INTRODUCTION
Hennekam lymphangiectasia- lymphedema syndrome- 1 
(HKLLS1) is a disorder of lymphedema, lymphangiectasis, 
and development delay. The edema is usually congenital and 
often progressive, generally including the limbs, genitalia, 
and face. Maldevelopment of the lymphatic system preferen-
tially affects the intestines and limbs, but can also affect other 
systems, such as the pleura, pericardium, and kidneys.1 This 
syndrome was first reported by Dr. Hennekam in 1989 as an 
autosomal recessive condition causing intestinal lymphangi-
ectasia, diffuse lymphedema, facial dysmorphisms (depressed 
nasal bridge, hypertelorism, narrow mouth, and deformi-
ties of the teeth and ears), and various degrees of growth 
impairment, cognitive disorders, and seizures.2 HKLLS1 is 
often caused by homozygous or compound heterozygous 
pathogenic variants in the collagen and calcium- binding 
EGF domain 1 (CCBE1) gene, an extracellular matrix pro-
tein essential to lymphatic system development.3 However, 
CCBE1 variants are only found in 25% of suspected cases.4 
Isolated or syndromic primary lymphedema has been associ-
ated with variants in 27 additional genes, including EPHB4, 
FLT4, FOXC2, GATA2, GJA1, GJC2, HGF, HRAS, IKBKG, 
ITGA9, KIF11, KRAS, PTPN11, PTPN14, RAF1, RASA1, 
SOS1, SOX18, VEGFC, CELSR1, EPHB4, FAT4, PIEZO1, 
RELN, RIT1, TSC1, TSC2, and ADAMTS3.5-7
Hydrops fetalis is defined as excessive fluid collections 
within fetal cavities and extravascular compartments: skin 
edema, ascites, pleural or pericardial effusions, thickened 
placenta, and polyhydramnios. It represents the end stage of 
a variety of disorders.8 Hydrops can be immune (isoimmu-
nization) and nonimmune, with up to 90% of current cases 
attributed to nonimmune causes,8,9 of which lymphatic dys-
plasias make up 5%- 15%. Nonimmune hydrops carries a poor 
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Key Clinical Message
Whole exome sequencing (WES) was used to determine the etiology of recurrent 
 hydrops fetalis in this case of Hennekam lymphangiectasia- lymphedema syndrome- 1. 
WES is a useful approach for diagnosing rare single- gene conditions with nonspecific 
phenotypes and should be considered early in the diagnostic process of investigating 
fetal abnormalities.
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prognosis, and fetal mortality ranges from 50%- 98%.8,10,11 
Unfortunately, despite recent advances in diagnostic capabil-
ities, 16%- 19% of cases remain idiopathic.9,11
Here, we report a case in which whole exome sequencing 
was used to diagnose the etiology of recurrent hydrops feta-
lis as HKLLS1 and to reveal a new pathologic variant in the 
CCBE1 gene.
2 |  CLINICAL CASE
The patient was a 39- year- old G4P1211 female of Northern 
European origin who presented to our institution with re-
current fetal hydrops. In her first pregnancy (managed at 
an outside institution), hydrops was diagnosed at 18 weeks. 
Anatomical survey was significant for unilateral clubfoot, 
without other abnormalities. Cardiac rhythm and middle cer-
ebral artery (MCA) Doppler velocimetry were normal, with-
out evidence of fetal anemia. The patient’s blood type was 
Rh- positive and antibody- negative. Amniocentesis revealed 
normal karyotype. Infectious workup was negative for par-
vovirus, cytomegalovirus, toxoplasmosis, herpes simplex 
virus, adenovirus, and coxsackie virus. Diabetes and thyroid 
studies were unremarkable. The patient elected termination, 
and a dilation and evacuation was performed at 22 weeks. No 
placental pathology was available. The final diagnosis was 
idiopathic hydrops.
In her second pregnancy, hydrops was again diag-
nosed at 18 weeks. Anatomical survey was normal, other 
than echogenic bowel. A full workup was performed, 
as described above for her first pregnancy, which was 
unremarkable. Maternal TSH was low (0.33 uIU/mL), 
but FT4 and FT3 were normal. TPO antibody was ele-
vated at 152 IU/mL. Additional normal testing included 
a Kleihauer- Betke acid elution for fetomaternal hemor-
rhage, testing for adenovirus, hemoglobin electrophore-
sis, and G6PD. She was referred to our institution for 
consultation, and cordocentesis was performed which 
confirmed normal fetal hematocrit. A lysosomal stor-
age disease panel was negative for GM1 gangliosidosis, 
mucopolysaccharidosis I and VII, Niemann- Pick disease 
types A and B, Gaucher disease, and sialidosis. The pa-
tient underwent induction termination at 22 weeks of 
gestation. An autopsy described a female fetus with a 
cystic hygroma, serous (nonchylous) pleural and peri-
cardial effusions, congested liver, hypoplastic lungs, 
and a “markedly enlarged, hyperplastic thyroid gland”. 
Cardiac anatomy, placental pathology, and karyotype 
were normal. Placental cultures were positive for com-
mon vaginal flora (Lactobacillus, Streptococcus vir-
idans, and diphtheroids) and negative for fungi and 
anaerobes. Maternal postpartum testing was negative for 
inherited thrombophilia and antiphospholipid antibodies. 
Antinuclear antibodies and TPO antibodies were positive.
In her third pregnancy, prenatal laboratories were un-
remarkable. Thyroid function was normal (TSH, FT4, T3, 
TSH, TRAB) other than elevated anti- TPO antibody (201 IU/
mL). Given a concern that fetal thyroid stimulation may be 
driving pathogenesis of hydrops, she was treated with prop-
ylthiouracil for fetal thyroid suppression from 12 to 31 weeks 
with add- back maternal levothyroxine. The pregnancy pro-
gressed to term, and the patient had spontaneous rupture 
of membranes at 38 weeks. Labor was augmented, and she 
delivered a morphologically normal male infant via normal 
spontaneous vaginal delivery, weighing 3625 g, with Apgars 
of 8 and 9. The infant was healthy and without thyroid or 
other metabolic disease. Neonatal thyroid studies were nor-
mal. Incidentally, following delivery, the patient was diag-
nosed with papillary thyroid cancer. This was not believed 
to be connected to the presence of anti- TPO antibodies. She 
underwent total thyroidectomy. Pathology revealed a stage 1 
multifocal papillary thyroid carcinoma arising in the back-
ground of lymphocytic thyroiditis with negative margins. 
She was started on levothyroxine and liothyronine sodium 
for postsurgical hypothyroidism. Radioiodine ablation was 
deferred due to desired future pregnancy.
In her fourth pregnancy, fetal hydrops was first noted at 
15 weeks (Figure 1). Prior to this diagnosis, she had nor-
mal first trimester screening and noninvasive prenatal test-
ing. Amniocentesis at 18 weeks returned 46, XY, inv(2)
(q14.2q23) male karyotype with suspected paracentric inver-
sion of 2q, which appeared balanced at the level of standard 
cytogenetic analysis. Fetal microarray was normal suggesting 
no detectable deletions or duplications at the breakpoints of 
this inversion. Maternal peripheral blood chromosome anal-
ysis showed the same inversion. An expanded carrier screen 
for 218 hereditary genetic disorders via Progenity’s Global 
Panel was negative. Paternal karyotype was normal. Fetal 
blood sampling was unremarkable, including normal fetal 
thyroid studies.
Given the history of recurrent hydrops, without any iden-
tifiable diagnosis, WES trio (with full exome sequencing of 
the parents as controls) was performed on fetal amniocytes. 
The next generation sequencing results showed compound 
heterozygous variants in the collagen and calcium- binding 
EGF domains 1 (CCBE1, NM_133459.3) gene, leading to 
the diagnosis of HKLLS1. Targeted Sanger sequencing was 
performed on parental and fetal samples confirming the iden-
tified variants (Figure 2).
Following fetal demise, dilation and evacuation was per-
formed. Autopsy was significant for mild- to- moderate lym-
phocyte depletion of the thymus, consistent with intrauterine 
hypoxic stress, and an excessively long, hyper- twisted umbil-
ical cord.
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The maternally inherited p.Leu229fs (c.683_684insT) 
pathogenic, loss- of- function variant in the CCBE1 gene 
is listed in the Genome Aggregation Database (gnomAD) 
Browser in 14 out of 277 032 chromosomes (rs563023244). 
This frameshift variant has been reported in a 20- year- old 
male patient who also carried another CCBE1 variant, 
 p.Arg158Cys3 and in a 52- year- old patient who also carried 
p.Asp104Asn CCBE1 variant on the other allele.12
The paternally inherited p.Thr112Ile (c.335C>T) likely 
pathogenic variant is rare, has not been published in the lit-
erature, and is listed in one out of 246 160 chromosomes in 
the gnomAD Browser. Threonine 112 is highly conserved, 
and the pathogenicity of this variant is supported by com-
putational prediction programs (SIFT, MutationTaster, and 
PolyPhen- 2). Thus, given this rare variant is located in the 
EGF- like calcium- binding domain, on the opposite chromo-
some of the loss- of- function variant, it is likely pathogenic, 
supporting the diagnosis of HKLLS1. Formalin- fixed fetal 
tissue from the second affected pregnancy was submitted for 
targeted analysis of the identified CCBE1 variants but good 
quality DNA could not be extracted on multiple attempts. 
DNA from the first affected pregnancy was not available. 
Therefore, confirmation of the variants was not possible in 
the other affected pregnancies. The unaffected sibling has not 
yet been tested.
3 |  DISCUSSION
Currently, first- line testing for fetal abnormalities identified 
by ultrasound usually consists of chromosome analysis and/
or genomic microarray testing. Chromosome analysis de-
termines the etiology of abnormalities in 9%- 19% of cases 
while genomic microarray provides additional clinically rel-
evant information in 6% of such cases.13,14 Therefore, in most 
cases, a cause for the fetal ultrasound abnormalities is not 
determined.
Next generation sequencing, including whole genome 
sequencing (WGS) and WES, was first popularized in the 
research realm to aid in the discovery of new, previously 
uncharacterized diseases. More recently, reverse phenotyp-
ing has employed the same technology to help make rare 
clinical diagnoses that are suspected to be of Mendelian 
(single- gene) genetic origin.15,16 Previously, targeted analy-
sis of candidate genes using specific predetermined probes, 
for example, florescent in situ hybridization, was needed. 
This, however, requires at least a suspicion of a particular 
disease or candidate gene, either by family history or clin-
ical phenotype.17 Unfortunately, many phenotypes discov-
ered via fetal ultrasound, especially nonimmune hydrops, 
are nonspecific.
Whole genome sequencing detects genetic variation in a 
patient’s entire genetic code, whereas WES investigates only 
the protein- coding regions and intron- exon borders. While 
exons make up only 1%- 2% of the human genome, 85% of 
variants implicated in genetic disorders are located in these 
coding regions.18 Exome sequencing is favored over genome 
sequencing in order to improve efficiency and decrease cost, 
thereby making it more accessible as a clinically available 
diagnostic tool.19
There are many case reports that describe using WES to 
aid in clinical diagnosis. More recent series have reported di-
agnostic yields of fetus and parents trios up to 24% in cases 
where standard genetic testing is normal.17 Unfortunately, 
WES remains limited by cost, lengthy turnaround time, di-
agnostic gaps, and the need for sophisticated genetic coun-
seling.20 Furthermore, WES is not reliable in detecting large 
F I G U R E  1  Ultrasound images of hydropic fetus from G4 
pregnancy. A, Fetal chest demonstrating pleural effusions; B, fetal head 
demonstrating scalp edema; C, fetal abdomen demonstrating ascites
(A)
(B)
(C)
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deletions/duplications/insertions, structural rearrangements, 
triple repeat expansions, mitochondrial DNA variants, or 
mosaic variants. Causative variants may be located in non-
coding regions analyzed by WGS, but this test is currently 
more expensive.21
In the above case, WES was used to identify a cause of 
recurrent fetal hydrops, not otherwise detected on extensive 
workup of multiple pregnancies, which included fetal karyo-
type and microarray. If WES had been ordered on the patient’s 
second pregnancy with fetal hydrops, perhaps after the nor-
mal microarray analysis, earlier diagnosis could have been 
established. WES identified compound heterozygosity in the 
CCBE1 gene consisting of a known pathogenic variant of ma-
ternal origin and a likely pathogenic variant of paternal origin. 
Unfortunately, complex segregation analysis could not be per-
formed due to inability to test the prior affected pregnancies.
CCBE1, located on chromosome 18q21, codes for a 
secreted protein that is required for lymphangiogenesis. 
During embryogenesis, development of the lymphatic sys-
tem occurs through a process of budding, migration, and 
proliferation of lymphocytic progenitor cells beginning 
during the 6th week of gestation. The CCBE1 gene encodes 
a signaling protein that is essential to the budding of lymph 
vessels from venous endothelium.10,22 CCBE1 knockout 
mice models have demonstrated an absence of lymphatic 
vessels, and affected mice die prenatally with severe hy-
drops.23 Homozygosity mapping has identified CCBE1 
gene variants to be a cause of HKLLS1.3 So far, at least 
F I G U R E  2  A compound heterozygous pathogenic mutations in CCBE1 gene were detected. (A and C) A paternally inherited variant, 
p.Thr112Ile (c.335C>T) variant was detected and confirmed by Sanger sequencing. (B and D) A maternally inherited variant, p.Leu229fs 
(c.683_684insT), was detected and confirmed by Sanger sequencing
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12 different CCBE1 variants have been reported in at least 
seventeen probands/families.3,4,12,24-29
In conclusion, WES was able to identify compound het-
erozygous pathogenic variants in the CCBE1 gene as a cause 
of HKLLS1 and recurrent fetal hydrops. The p.Thr112Ile 
variant has never been described, but alters a highly con-
served sequence and is predicted to be pathogenic. As in our 
case, WES may provide a definitive diagnosis for cases of 
idiopathic nonimmune hydrops, allowing recurrence risk 
counseling, facilitating preconception counseling, and lead-
ing to informed future reproductive choices, such as preim-
plantation genetic diagnosis and earlier prenatal diagnosis 
with chorionic villus sampling.
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